Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Molecular Diagnosis & Therapy
Erschienen in: Molecular Diagnosis & Therapy 5/2014

01.10.2014 | Review Article

Positron Emission Tomography Diagnostic Imaging in Multidrug-Resistant Hepatocellular Carcinoma: Focus on 2-Deoxy-2-(18F)Fluoro-d-Glucose

verfasst von: Ana F. Brito, Mónica Mendes, Ana M. Abrantes, José G. Tralhão, Maria F. Botelho

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Surgical resection and liver transplantation are still the best options for treatment. Nevertheless, as the number of patients who may benefit from these therapies is limited, alternative therapies have been developed, including chemotherapy. However, partly due to the expression of multidrug resistance (MDR) proteins, it has been found that HCC is a highly chemoresistant tumor. The major family of MDR proteins is the ATP-binding cassette (ABC) transporter superfamily, which includes P-glycoprotein (Pgp) and MDR-associated protein 1 (MRP1). Positron emission tomography using the radiolabeled analog of glucose, 2-deoxy-2-(18F)fluoro-d-glucose ([18F]FDG), has been used in diagnostic imaging of various types of tumors. Clinical studies are inconsistent but experimental studies have shown that [18F]FDG uptake is associated with tumor grade and is inversely proportional to Pgp expression in HCC. These studies unveil that [18F]FDG can be a substrate of Pgp, although that relationship remains unclear. This review sums up the relationship between MDR expression in HCC, and [18F]FDG uptake by tumor cells, showing that this radiopharmaceutical may provide a useful tool for the study of chemoresistance in HCC, and that the use of this marker may contribute to the therapeutic choice on this highly aggressive tumor.
Literatur
1.
2.
Skelton M, O’Neil B. Targeted therapies for hepatocellular carcinoma. Clin Adv Hematol Oncol. 2008;6(3):209–18.PubMed
3.
Brito AF, Abrantes AM, Pinto-Costa C, Gomes AR, Mamede AC, Casalta-Lopes J, et al. Hepatocellular carcinoma and chemotherapy: the role of p53. Chemotherapy. 2012;58(5):381–6. doi:10.​1159/​000343656.PubMedCrossRef
4.
5.
6.
7.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.PubMedCrossRef
8.
9.
Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M, et al. Advanced hepatocellular carcinoma: review of targeted molecular drugs. Ann Hepatol. 2011;10(1):21–7.PubMed
10.
Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796–800.PubMedCrossRef
11.
Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska Immunization Program. J Infect Dis. 2000;181(2):413–8.PubMedCrossRef
12.
Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology. 2002;181–182:43–7.PubMedCrossRef
13.
14.
15.
16.
Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29(1–2):130–43.PubMedCrossRef
17.
18.
Casalta-Lopes J, Abrantes AM, Laranjo M, Rio J, Gonçalves AC, Oliveiros B, et al. Efflux pumps modulation in colorectal adenocarcinoma cell lines: the role of nuclear medicine. J Cancer Ther. 2011;02(03):408–17. doi:10.​4236/​jct.​2011.​23056.CrossRef
19.
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.PubMedCrossRef
20.
21.
22.
23.
Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci. 1991;98(Pt 3):317–22.PubMed
24.
Krishnakumar S, Mallikarjuna K, Desai N, Muthialu A, Venkatesan N, Sundaram A, et al. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol. 2004;88(12):1521–6.PubMedPubMedCentralCrossRef
25.
Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008;28(10):1370–80. doi:10.​1111/​j.​1478-3231.​2008.​01889.​x.PubMedCrossRef
26.
27.
Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204(3):216–37.PubMedCrossRef
28.
Sharom F. Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. Front Oncol. 2013;4(41):1–19. doi:10.​3389/​fonc.​2014.​00041.
29.
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22(47):7468–85.PubMedCrossRef
30.
Teodori E, Dei S, Scapecchi S, Gualtieri F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco. 2002;57(5):385–415.PubMedCrossRef
31.
Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 2000;65(1):95–106.
32.
Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–92.PubMedCrossRef
33.
34.
Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta. 1999;1461(2):347–57.PubMedCrossRef
35.
Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta. 1999;1461(2):359–76.PubMedCrossRef
36.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–62.PubMedCrossRef
37.
Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res. 2007;55(1):1–15.PubMedCrossRef
38.
Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev. 1996;6(5):610–7.PubMedCrossRef
39.
Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2000;1(1):85–99.PubMedCrossRef
40.
Chen YB, Yan ML, Gong JP, Xia RP, Liu LX, Li N, et al. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1. Chin Med J (Engl). 2007;120(8):703–7.
41.
Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol. 2000;113(3):355–63.PubMedCrossRef
42.
Isshiki K, Nakao A, Ito M, Hamaguchi M, Takagi H. P-glycoprotein expression in hepatocellular carcinoma. J Surg Oncol. 1993;52(1):21–5.PubMedCrossRef
43.
Soini Y, Virkajärvi N, Raunio H, Pääkkö P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol. 1996;49(6):470–3.PubMedPubMedCentralCrossRef
44.
Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol. 1997;12(8):569–75.PubMedCrossRef
45.
Grudé P, Conti F, Mennecier D, Louvel A, Houssin D, Weill B, et al. MDR1 gene expression in hepatocellular carcinoma and the peritumoral liver of patients with and without cirrhosis. Cancer Lett. 2002;186(1):107–13.PubMedCrossRef
46.
Bonin S, Pascolo L, Crocé LS, Stanta G, Tiribelli C. Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol Med. 2002;8(6):318–25.PubMedPubMedCentral
47.
Sun Z, Zhao Z, Li G, Dong S, Huang Z, Ye L, et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori. 2010;96(1):90–6.PubMed
48.
49.
Tada K, Iwai M, Ishii Y, Kitagawa Y, Kashiwadani M, Nakashima T, et al. P-glycoprotein expression in hepatocellular carcinoma-from the view of histological differentiation and chemotherapy. Int Hepatol Commun. 1995;3:158.CrossRef
50.
Wang H, Chen XP, Qiu FZ. Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10(9):1281–5.PubMed
51.
Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19(13):1946–2025.PubMedCrossRef
52.
Szakács G, Homolya L, Sarkadi B, Váradi A. MDR-ABC transporters. Encyclopedia of Molecular Pharmacology;2008: p. 748–52.
53.
54.
Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol. 2003;200(5):553–60.PubMedCrossRef
55.
Wang BL, Chen XP, Zhai SP, Chen DF. Clinical significance of mrp gene in primary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2003;2(3):397–403.PubMed
56.
57.
Gasparre G, Porcelli AM, Lenaz G, Romeo G. Relevance of mitochondrial genetics and metabolism in cancer development. Cold Spring Harb Perspect Biol. 2013;5(2). doi:10.​1101/​cshperspect.​a011411.
58.
Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007;274:1393–418.PubMedCrossRef
59.
60.
61.
62.
63.
64.
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9.PubMedCrossRef
65.
66.
67.
68.
De Gaetano AM, Rufini V, Castaldi P, Gatto AM, Filograna L, Giordano A, et al. Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors. Abdom Imaging. 2012;37(6):983–1003. doi:10.​1007/​s00261-012-9845-y.PubMedCrossRef
69.
Raddatz D, Ramadori G. Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z Gastroenterol. 2007;45(1):51–62.PubMedCrossRef
70.
Amann T, Maegdefrau U, Hartmann A, Stoeltzing O, Weiss TS, Warnecke C, et al. GLUT1 and GLUT3 expression are increased in hepatocellular carcinoma and promote tumorigenesis. Z Gastroenterol. 2009;47:p3_01. doi:10.​1055/​s-0029-1191858.CrossRef
71.
72.
Salem N, MacLennan GT, Kuang Y, Anderson PW, Schomisch SJ, Tochkov IA, et al. Quantitative evaluation of 2-deoxy-2[F-18]fluoro-d-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol. 2007;9(3):135–43.PubMedCrossRef
73.
Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011;197(2):W260–5. doi:10.​2214/​AJR.​11.​6995.PubMedCrossRef
74.
Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32(5):792–7.PubMedCrossRef
75.
76.
Wolfort RM, Papillion PW, Turnage RH, Lillien DL, Ramaswamy MR, Zibari GB. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg. 2010;95(1):67–75.PubMed
77.
78.
Higashi K, Ueda Y, Ikeda R, Kodama Y, Guo J, Matsunari I, et al. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. Nucl Med Commun. 2004;25(1):19–27.PubMedCrossRef
79.
Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008;143(6):769–77. doi:10.​1016/​j.​surg.​2008.​01.​010.PubMedCrossRef
80.
Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13(2 Pt 1):427–33.PubMedCrossRef
81.
Lorke DE, Krüger M, Buchert R, Bohuslavizki KH, Clausen M, Schumacher U. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J Nucl Med. 2001;42(4):646–54.PubMed
82.
Bentley J, Quinn DM, Pitman RS, Warr JR, Kellett GL. The human KB multidrug-resistant cell line KB-Cl is hypersensitive to inhibitors of glycosylation. Cancer Lett. 1997;115(2):221–7.PubMedCrossRef
83.
Yamada K, Brink I, Engelhardt R. Factors influencing [F-18] 2-fluoro-2-deoxy-d-glucose (F-18 FDG) accumulation in melanoma cells: is FDG a substrate of multidrug resistance (MDR)? J Dermatol. 2005;32(5):335–45.PubMedCrossRef
84.
Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. P-glycoprotein expression affects 18 F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol. 2009;34(5):1303–12.PubMed
85.
86.
87.
Chang CS, Huang WT, Yang SS, Yeh HZ, Kao CH, Chen GH. Effect of P-glycoprotein and multidrug resistance associated protein gene expression on Tc-99m MIBI imaging in hepatocellular carcinoma. Nucl Med Biol. 2003;30(2):111–7.PubMedCrossRef
88.
Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci. 1991;98(3):317–22.PubMed
89.
Márián T, Szabó G, Goda K, Nagy H, Szincsák N, Juhász I, et al. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Eur J Nucl Med Mol Imaging. 2003;30(8):1147–54.PubMedCrossRef
90.
91.
Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 2007;453(5):601–10.CrossRef
92.
93.
Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11(7):1156–66.PubMedCrossRef
94.
Paterson J, Shukla S, Black C, Tachiwada T, Garfield S, Wincovitch S, et al. Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry. 2007;46:9443–52.PubMedCrossRef
95.
96.
Staud F, Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol. 2005;37(4):720–5.PubMedCrossRef
97.
Mack J, Townsend D, Beljanski V, Tew K. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr Drug Metab. 2007;8:47–57.PubMedCrossRef
Metadaten
Titel
Positron Emission Tomography Diagnostic Imaging in Multidrug-Resistant Hepatocellular Carcinoma: Focus on 2-Deoxy-2-(18F)Fluoro-d-Glucose
verfasst von
Ana F. Brito
Mónica Mendes
Ana M. Abrantes
José G. Tralhão
Maria F. Botelho
Publikationsdatum
01.10.2014
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 5/2014
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-014-0106-3

Weitere Artikel der Ausgabe 5/2014

Molecular Diagnosis & Therapy 5/2014 Zur Ausgabe

Original Research Article

Development and Validation of a Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction Combined with Melting Analysis-Assay for Clinical JAK2 V617F Mutation Detection

Original Research Article

Evaluation of a New High-Throughput Next-Generation Sequencing Method Based on a Custom AmpliSeq™ Library and Ion Torrent PGM™ Sequencing for the Rapid Detection of Genetic Variations in Long QT Syndrome

Original Research Article

Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome of Chemotherapy- and Radiotherapy-Treated Colorectal Adenocarcinoma Patients

Current Opinion

Blood-Based Biomarkers in Depression: Emerging Themes in Clinical Research

Original Research Article

Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder

Review Article

Oncoapoptotic Markers in Oral Cancer: Prognostics and Therapeutic Perspective

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise